UNDERWRITING AGREEMENTUnderwriting Agreement • October 12th, 2021 • Biofrontera Inc. • Pharmaceutical preparations • New York
The undersigned, Biofrontera Inc., a company incorporated under the laws of Delaware (collectively with its subsidiaries, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries of Biofrontera, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representatives (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Roth Capital Partners, LLC and The Benchmark Company, LLC are acting as representatives to the several Underwriters (the “Representatives” and if there are no Underwriters other than the Representatives, references to multiple Underwriters shall be disregarded and the term Representatives as used herein shall have the same meaning as “Underwriter”) on the terms and conditions set forth herein.
BIOFRONTERA INC. NONQUALIFIED STOCK OPTION AWARD AGREEMENTNonqualified Stock Option Award Agreement • October 12th, 2021 • Biofrontera Inc. • Pharmaceutical preparations • Delaware
THIS NONQUALIFIED STOCK OPTION AWARD AGREEMENT (this “Agreement”), dated as of [________], 2021 (the “Date of Grant”), is made by and between Biofrontera Inc. (the “Company”), and [_______] (the “Participant”).
BIOFRONTERA INC. RESTRICTED STOCK UNIT EXECUTIVE AWARD AGREEMENTRestricted Stock Unit • October 12th, 2021 • Biofrontera Inc. • Pharmaceutical preparations • Delaware
THIS RESTRICTED STOCK UNIT AWARD AGREEMENT (this “Agreement”), dated as of [_________], 2021 (the “Date of Grant”), is made by and between Biofrontera Inc. (the “Company”), and [_______] (the “Participant”).
BIOFRONTERA INC. NONQUALIFIED STOCK OPTION EXECUTIVE AWARD AGREEMENTNonqualified Stock Option Executive Award Agreement • October 12th, 2021 • Biofrontera Inc. • Pharmaceutical preparations • Delaware
THIS NONQUALIFIED STOCK OPTION AWARD AGREEMENT (this “Agreement”), dated as of [________], 2021 (the “Date of Grant”), is made by and between Biofrontera Inc. (the “Company”), and [_______] (the “Participant”).
Amendment to Amended and Restated License and Supply AgreementLicense and Supply Agreement • October 12th, 2021 • Biofrontera Inc. • Pharmaceutical preparations
This Second Amendment to License and Supply Agreement (the “Amendment”) is made effective as of October 8, 2021, by and between Biofrontera Pharma GmbH, a German corporation with its principal offices at Hemmelrather Weg 201, 51377 Leverkusen, Germany (“PHARMA”), Biofrontera Bioscience GmbH, a German corporation with its principal offices at Hemmelrather Weg 201, 51377 Leverkusen, Germany (“BIOSCIENCE”) and Biofrontera Inc., a Delaware corporation with its principal place of business at 120 Presidential Way, Woburn, MA 01801, USA (“INC”). PHARMA, BIOSCIENCE, and Inc may collectively be referred to as the “Parties” or individually as a “Party.” Capitalized terms used but not defined herein shall have the meanings assigned to them in the LSA.
